Mipharm S.p.A
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mipharm S.p.A - overview
Location
Milan, -, Italy
Primary Industry
Pharmaceuticals
About
Mipharm S. p. A is a technology company based in Milan, Italy, specializing in innovative solutions that enhance operational efficiency across diverse industries such as healthcare and manufacturing. Founded in Milan, Italy, Mipharm S.
p. A focuses on delivering technology solutions to various sectors. In March 2022, Alto Partners and DVR&C Private Equity acquired the company from Mindful Capital Partners as part of a strategic buyout. The company has successfully completed 2 deals to date, raising EUR 16.
40 mn through its latest funding round. Paolo De Matteis serves as the CEO. Mipharm S. p.
A provides a suite of software applications designed to streamline workflows and optimize resource management. Their innovations cater to a diverse client base, including small to medium-sized enterprises and large corporations, primarily in the healthcare, finance, and manufacturing sectors. Recent iterations of these applications have been specifically developed based on user feedback, allowing the company to penetrate markets in North America, Europe, and Asia-Pacific. In the most recent fiscal year, Mipharm S.
p. A reported a revenue of EUR 54,720,396. 50 and an EBITDA of EUR 9,867,946. 20.
The company’s revenue model is built on subscription-based services and direct sales, fostering long-term relationships with clients through continuous updates and additional features. Mipharm S. p. A plans to leverage the EUR 16.
40 mn raised in its recent Buyout round to expand its product offerings and enhance its market presence. Upcoming new products are in the design phase with expected launches targeted for late 2023. Additionally, the company aims to enter new geographic markets, specifically targeting expansion in South America and the Middle East by 2024. The recent acquisition will further bolster Mipharm's growth strategy as it seeks to solidify its position in the technology solutions sector.
Current Investors
Alto Partners, DVR&C Private Equity
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.mipharm.eu
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Mipharm S.p.A - timeline of key events
Mipharm S.p.A - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 31,654,534 | 34,501,669 | 35,701,499 | 35,084,169 | 35,637,182 | 36,504,304 | 38,150,868 | 41,627,231 | 43,405,825 | 40,020,732 | 40,046,571 | - | - | - |
| % Revenue Growth (YoY) | - | 9.0% | 3.5% | (1.7%) | 1.6% | 2.4% | 4.5% | 9.1% | 4.3% | (7.8%) | 0.1% | - | - | - |
| EBITDA (USD) | 5,406,293 | 6,283,409 | 5,416,090 | 5,525,192 | 3,480,219 | 4,744,695 | 3,846,553 | 6,222,914 | 7,029,753 | 2,506,742 | 5,210,028 | - | - | - |
| Operating Income (USD) | 4,492,679 | 5,359,355 | 4,493,627 | 4,553,652 | 2,471,372 | 3,645,575 | 2,712,804 | 3,221,507 | 3,896,810 | (976,970) | 1,554,177 | - | - | - |
| Operating Margin | 14.2% | 15.5% | 12.6% | 13.0% | 6.9% | 10.0% | 7.1% | 7.7% | 9.0% | (2.4%) | 3.9% | - | - | - |
| % EBITDA Margin | 17.1% | 18.2% | 15.2% | 15.7% | 9.8% | 13.0% | 10.1% | 14.9% | 16.2% | 6.3% | 13.0% | - | - | - |
| NET Income (USD) | 2,749,522 | 3,101,216 | 2,662,025 | 2,913,333 | 162,449 | 2,069,725 | 811,815 | 1,376,017 | 1,969,873 | (1,840,401) | 447,268 | - | - | - |
| % Net Margin | 8.7% | 9.0% | 7.5% | 8.3% | 0.5% | 5.7% | 2.1% | 3.3% | 4.5% | (4.6%) | 1.1% | - | - | - |
Mipharm S.p.A - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | Mipharm S.p.A | - | ||||||||
| Buyout | Completed | Mipharm S.p.A | - |
Displaying 1 - 2 of 2
Mipharm S.p.A - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.